DNAtrix Revenue and Competitors
Estimated Revenue & Valuation
- DNAtrix's estimated annual revenue is currently $620k per year.
- DNAtrix's estimated revenue per employee is $155,000
Employee Data
- DNAtrix has 4 Employees.
- DNAtrix grew their employee count by -20% last year.
DNAtrix's People
| Name | Title | Email/Phone |
|---|---|---|
1 | VP Translational Research | Reveal Email/Phone |
2 | Director Clinical Operations | Reveal Email/Phone |
3 | Chief Medical Officer | Reveal Email/Phone |
DNAtrix Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $1.7M | 11 | -8% | N/A | N/A |
#2 | $14.9M | 96 | -6% | N/A | N/A |
#3 | $15.2M | 98 | 3% | $1.8M | N/A |
#4 | $1.6M | 10 | 0% | N/A | N/A |
#5 | $3.4M | 22 | 0% | N/A | N/A |
#6 | $2.8M | 18 | 50% | N/A | N/A |
#7 | $7.4M | 48 | -2% | N/A | N/A |
#8 | $0.8M | 5 | 0% | N/A | N/A |
#9 | $1.6M | 10 | 0% | N/A | N/A |
#10 | $16.3M | 105 | 62% | N/A | N/A |
What Is DNAtrix?
DNAtrix is a privately held biotech company developing virus-driven immunotherapies to treat cancer. Its proprietary adenovirus platform is based on an engineered version of the common cold virus that is designed to selectively infect and kill cancer cells while leaving healthy cells unharmed. The company's lead product candidate is DNX-2401, which is expected to enter into a global pivotal Phase 3 clinical study for patients with recurrent glioblastoma. DNX-2401 is also being evaluated in a Phase 1 study for diffuse intrinsic pontine glioma, for which it has received FDA Fast Track and Rare Pediatric Disease designations. A second product candidate, DNX-2440, is entering a Phase 1 clinical study in patients with colorectal and other cancers with liver metastasis. The company's investors include Morningside Ventures and Mercury Fund.
keywords:N/A
N/A
Total Funding
4
Number of Employees
$620k
Revenue (est)
-20%
Employee Growth %
N/A
Valuation
N/A
Accelerator
DNAtrix News
Some of the Top companies Influencing in this Market includes: Eli Lilly and Company, Bedford Laboratories, DNAtrix, Inc., Astellas US Holding,...
The following businesses were investigated as part of the study: Eli Lilly; Astellas; DNAtrix; Advantagene; Burzynski Research Institute; Direct...
Other Companies in Houston
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $0.5M | 4 | 0% | N/A |
#2 | $0.7M | 4 | -83% | N/A |
#3 | $0.3M | 4 | N/A | N/A |
#4 | $0.4M | 4 | N/A | N/A |
#5 | $0.4M | 4 | N/A | N/A |